This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
O-GlcNAcase
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | <StructureSection load=' | + | <StructureSection load='5m7u' size='340' side='right' caption='Caption for this structure' scene=''> |
| - | + | ||
== Function == | == Function == | ||
| - | '''O-GlcNAcase''' or '''hyaluronoglucosaminidase''' (OGA) | + | '''O-GlcNAcase''' or '''hyaluronoglucosaminidase''' (OGA) is one of two enzymes which modulate the level of O-linked N-acetylglucosamine (O-GlcNAc) attachment to cytoplasmic, nuclear and mitochondrial proteins<ref>PMID:22311971</ref>. The attachment of O-GlcNAc to proteins is a post-translational modification. |
== Disease == | == Disease == | ||
== Relevance == | == Relevance == | ||
| + | |||
| + | Inhibition of OGA is a promising therapeutic approach to treat tau pathology in neurodegenerative diseases such as Alzheimer's disease and progressive supranuclear palsy<ref>PMID:31487175</ref>. | ||
== Structural highlights == | == Structural highlights == | ||
Revision as of 09:04, 1 October 2020
| |||||||||||
3D structures of O-GlcNAcase
Updated on 01-October-2020
References
- ↑ Shen DL, Gloster TM, Yuzwa SA, Vocadlo DJ. Insights into O-linked N-acetylglucosamine ([0-9]O-GlcNAc) processing and dynamics through kinetic analysis of O-GlcNAc transferase and O-GlcNAcase activity on protein substrates. J Biol Chem. 2012 May 4;287(19):15395-408. doi: 10.1074/jbc.M111.310664. Epub, 2012 Feb 6. PMID:22311971 doi:http://dx.doi.org/10.1074/jbc.M111.310664
- ↑ Selnick HG, Hess JF, Tang C, Liu K, Schachter JB, Ballard JE, Marcus J, Klein DJ, Wang X, Pearson M, Savage MJ, Kaul R, Li TS, Vocadlo DJ, Zhou Y, Zhu Y, Mu C, Wang Y, Wei Z, Bai C, Duffy JL, McEachern EJ. Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies. J Med Chem. 2019 Nov 27;62(22):10062-10097. doi: 10.1021/acs.jmedchem.9b01090., Epub 2019 Sep 29. PMID:31487175 doi:http://dx.doi.org/10.1021/acs.jmedchem.9b01090
